SCHEMBL1202836

SCHEMBL1202836

CN(Cc1ccc(Cl)c(Cl)c1)c1ccc2ncc([N+](=O)[O-])n2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 1/20 0.39
▸ NTRK3 Q16288 1/20 0.39
▸ NTRK2 Q16620 1/20 0.39
▸ CRHR1 P34998 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ IKBKB O14920 5/20 0.36
▸ HTT P42858 2/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HKDC1 Q2TB90 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ FYN P06241 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1203079 0.73 KCNH2 (0.44) NTRK1NTRK3NTRK2IKBKBHTT
SCHEMBL430605 0.69 TNF (0.50) ALDH1A1GAASMN1; SMN2KDM4ECYP1A2
SCHEMBL16371453 0.64 NTRK1 (0.50) NTRK1NTRK3NTRK2ALDH1A1GAA
SCHEMBL7984001 0.64 CYP1A2 (0.46) ALDH1A1GAASMN1; SMN2KDM4ELMNA
SCHEMBL2902233 0.64 CYP1A2 (0.46) ALDH1A1GAAIKBKBKDM4ELMNA
SCHEMBL22834815 0.64 CYP1A2 (0.47) KDM4EFYNCYP1A2CYP2C9MEN1
SCHEMBL7998348 0.63 CYP1A2 (0.45) ALDH1A1GAANPSR1KDM4ELMNA
SCHEMBL16371971 0.62 NTRK1 (0.60) NTRK1NTRK3NTRK2ALDH1A1GAA
SCHEMBL11734584 0.62 CYP1A2 (0.43) ALDH1A1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL1203027 0.62 NTRK1 (0.48) NTRK1NTRK3NTRK2HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-02-24 — — US disclosed
EP-2217601-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-08-18 — — EP disclosed
WO-2009060197-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 NTRK1 755/4885NTRK3 756/4885NTRK2 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback